Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Ireland

European Innovation Council · Running

Endoprotease 40 (E40) First ever preventive treatment for celiac disease and gluten sensitivity

Coordinator
Nemysis Limited, Ireland
Runs
1 June 2023 to 31 December 2025
Status
Running
EU funding
€2.5m
Total cost
€4.2m
Partners
1 organisations in 1 countries
Type
European Innovation Council
Grant agreement
190138713

What the project is doing

In the project's own words, from its summary on CORDIS.

E40 is a novel gluten degrading enzyme aimed at enhancing the degradation of ingested gluten, particularly in gluten intolerant Celiac Disease (CeD) and Non-Celiac Gluten Sensitivity (NCGS) sufferers. Different from any other competing enzymes under development, E40 efficiently exerts its gluten degrading activity in both the stomach and the intestine of CeD and NCGS sufferers, supporting the benefits of a Gluten Free Diet (GFD).

The final goal is to prevent symptomatology due to the pro-inflammatory reaction triggered by gluten. E40 will allow sufferers to manage inadvertent gluten exposure and will improve sufferer's Quality of Life, in particular allowing them to normalise their work and social life, reducing anxiety and allowing them to enjoy many everyday activities, like eating in a restaurant, travelling and visiting their friends in their homes.

E40 is produced by an engineered, patented acidic Streptomyces lividans TK24 strain, and directly purified in its mature, functional form. E40 activity has already been confirmed using the validated human simulated digestion INFOGEST assay of real food digestion: E40 gluten degradation leads to a gluten-free status (residual gluten<20ppm as per EC guidelines).

Topics

Who is involved

OrganisationCityCountryRole
Nemysis LimitedDublinIrelandCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI